Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.93% of ...

State Street Corp raised its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 30.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 174,529 shares of the ...

SELLAS Life Sciences will hold a corporate update call on January 8, 2025, discussing its 2025 outlook and clinical developments. SELLAS Life Sciences Group, Inc. announced it will hold a ...

For more information on the study, visit clinicaltrial.gov identifier NCT04588922. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the ...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...

2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached - NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASD - GPS Currently ...

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall ...

For more information on the study, visit clinicaltrial.gov identifier NCT04588922. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...